Design Therapeutics (NASDAQ:DSGN – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.02, FiscalAI reports.
Design Therapeutics Price Performance
Shares of DSGN traded up $0.58 during midday trading on Friday, hitting $10.26. The stock had a trading volume of 175,078 shares, compared to its average volume of 584,260. Design Therapeutics has a 1 year low of $6.68 and a 1 year high of $17.25. The firm has a market cap of $641.78 million, a PE ratio of -8.54 and a beta of 1.73. The stock’s 50 day moving average is $12.24 and its 200 day moving average is $12.14.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on DSGN shares. Royal Bank Of Canada cut their price target on Design Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Thursday. Wells Fargo & Company assumed coverage on Design Therapeutics in a research report on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Design Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.57.
Get Our Latest Stock Report on DSGN
About Design Therapeutics
Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.
The company’s research has focused on disorders affecting the nervous system, muscles and eyes.
Further Reading
- Five stocks we like better than Design Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
